Edition:
India

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

186.41USD
13 Sep 2019
Change (% chg)

$-1.61 (-0.86%)
Prev Close
$188.02
Open
$188.18
Day's High
$190.59
Day's Low
$186.37
Volume
140,380
Avg. Vol
214,276
52-wk High
$458.50
52-wk Low
$180.17

Latest Key Developments (Source: Significant Developments)

Abiomed Comments On Centers For Medicare & Medicaid Services Final Rule For Inpatient Prospective Payment System
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Abiomed Inc ::ABIOMED INC - COMMENTS ON CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) FINAL RULE FOR INPATIENT PROSPECTIVE PAYMENT SYSTEM (IPPS).  Full Article

Abiomed Q1 GAAP Earnings Per Share $1.93
Thursday, 1 Aug 2019 

Aug 1 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES Q1 FY 2020 REVENUE OF $208 MILLION AND 29.2% OPERATING MARGIN.Q1 GAAP EARNINGS PER SHARE $1.93.SEES FY 2020 REVENUE UP 15 TO 20 PERCENT.SEES FY 2020 REVENUE $885 MILLION TO $925 MILLION.Q1 REVENUE $208 MILLION VERSUS REFINITIV IBES ESTIMATE OF $210.7 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.97 -- REFINITIV IBES DATA.BOARD OF DIRECTORS HAS AUTHORIZED REPURCHASE OF UP TO $200 MILLION OF COMPANY'S COMMON STOCK.REVISING FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 28% TO 30%.FY2020 REVENUE VIEW $927.1 MILLION -- REFINITIV IBES DATA.  Full Article

Abiomed Says CEO's FY 2019 Total Compensation Was $19.2 Mln Versus $10.3 Mln In FY 2018
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Abiomed Inc ::ABIOMED INC SAYS CEO MICHAEL MINOGUE'S FY 2019 TOTAL COMPENSATION WAS $19.2 MILLION VERSUS $10.3 MILLION IN FY 2018 - SEC FILING.ABIOMED INC SAYS FOR FISCAL 2019, ESTIMATE RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN ANNUAL TOTAL COMPENSATION OF EMPLOYEES ABOUT 166 TO 1.  Full Article

FDA Confirms Impella Rp Is Safe And Effective Only Right-Sided Device With FDA Approval
Tuesday, 21 May 2019 

May 21 (Reuters) - Abiomed Inc ::FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE; ONLY RIGHT-SIDED DEVICE WITH FDA APPROVAL.ABIOMED INC - FDA CONFIRMS IMPELLA RP IS SAFE AND EFFECTIVE.ABIOMED INC - 18-MONTH PAS REPORT HAS BEEN ACCEPTED BY FDA AND IS SUCCESSFULLY CLOSED..ABIOMED INC - FDA HAS NO SAFETY CONCERNS ABOUT IMPELLA RP ITSELF.  Full Article

Abiomed Q4 GAAP Earnings Per Share $1.60
Thursday, 2 May 2019 

Abiomed Inc ::ABIOMED ANNOUNCED Q4 FY 2019 REVENUE OF $207 MILLION AND 31.6% OPERATING MARGIN.Q4 GAAP EARNINGS PER SHARE $1.60.Q4 REVENUE $207.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $218.9 MILLION.SEES FY 2020 REVENUE UP 17 TO 23 PERCENT.SEES FY 2020 REVENUE $900 MILLION TO $945 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $1.08 -- REFINITIV IBES DATA.SAYS "Q4 DID NOT MEET OUR EXPECTATIONS".COMPANY IS GIVING ITS FISCAL YEAR 2020 GUIDANCE FOR GAAP OPERATING MARGIN TO BE IN RANGE OF 29% TO 31%.FY2020 REVENUE VIEW $988.7 MILLION -- REFINITIV IBES DATA.  Full Article

Abiomed Reports 6 Pct Stake In Shockwave Medical
Saturday, 23 Mar 2019 

March 22 (Reuters) - Abiomed Inc ::ABIOMED REPORTS 6 PERCENT STAKE IN SHOCKWAVE MEDICAL AS OF MARCH 11 - SEC FILING.ABIOMED- ACQUIRED SHOCKWAVE SHARES ON ASSESSMENT OF POTENTIAL SYNERGIES BETWEEN CO, SHOCKWAVE PRODUCT OFFERINGS, BELIEF IT IS "ATTRACTIVE INVESTMENT".ABIOMED - MAY SEEK TO ENGAGE IN TALKS WITH SHOCKWAVE ABOUT POTENTIAL BUSINESS DEALS.  Full Article

Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor
Monday, 2 Apr 2018 

April 2 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR.MARKET APPROVAL FOR ITS IMPELLA CP HEART PUMP WITH SMARTASSIST.  Full Article

Abiomed To Appoint Todd Trapp Chief Financial Officer
Friday, 30 Mar 2018 

March 30 (Reuters) - Abiomed Inc ::ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP.ABIOMED INC - ‍TODD A. TRAPP WILL BE APPOINTED AS VICE PRESIDENT AND CFO, EFFECTIVE APRIL 9, 2018​.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES.  Full Article

Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - Abiomed Inc ::ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK.ABIOMED INC - APPROVAL EXPANDS PREVIOUS FDA INDICATION FOR ACUTE MYOCARDIAL INFARCTION CARDIOGENIC SHOCK AND PCCS, RECEIVED IN APRIL 2016.  Full Article